Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
This article is the first in a four-part series that reviews recent literature on cutaneous adverse reactions experienced with commonly prescribed biologic and targeted therapies, specifically tumor necrosis factor (TNF) alpha inhibitors, epidermal growth factor receptor (EGFR) inhibitors, small-molecule tyrosine kinase inhibitors (TKIs), and frequently used cell surface-targeted monoclonal antibodies
Likewise, as patients progress and require triple therapy, these medication classes comprise options in combination with a variety of other antihyperglycemic medication classes
Researchers continue to study these potential benefits, and individual results may vary
That small addition is the game-changer
2023;35(8):1406-23.e8
US$ 23.53
US$ 28.07
US$ 28.86
US$ 23.06
US$ 26.85
